Clinical characteristics of Japanese patients with moderate to severe COVID-19

被引:6
|
作者
Otoshi, Ryota [1 ]
Hagiwara, Eri [1 ]
Kitayama, Takaaki [1 ]
Yamaya, Takafumi [1 ]
Higa, Katsuyuki [1 ]
Murohashi, Kota [1 ]
Sato, Yozo [1 ]
Tabata, Erina [1 ]
Shintani, Ryota [1 ]
Okabayashi, Hiroko [1 ]
Ikeda, Satoshi [1 ]
Niwa, Takashi [1 ]
Nakazawa, Atsuhito [1 ]
Oda, Tsuneyuki [1 ]
Okuda, Ryo [1 ]
Sekine, Akiamasa [1 ]
Kitamura, Hideya [1 ]
Baba, Tomohisa [1 ]
Komatsu, Shigeru [1 ]
Ogura, Takashi [1 ]
机构
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
关键词
COVID-19; Coronavirus; SARS-CoV-2; Severity; Respiratory failure; CORONAVIRUS DISEASE 2019;
D O I
10.1016/j.jiac.2021.02.028
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient's characteristics whose disease progressed to severe status. Methods: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1-4 L/min), and severe diseases (oxygen needs of 5 L/min or more). Results: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. Conclusions: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:895 / 901
页数:7
相关论文
共 50 条
  • [1] Clinical Outcomes and Prevalence of Sarcopenia in Patients with Moderate to Severe COVID-19
    Yamamoto, Shuhei
    Sakai, Yasunari
    Matsumori, Keiji
    Osawa, Ryuji
    Ito, Shun
    Tsukakoshi, Daichi
    Ohno, Tomoki
    Ohta, Hiroaki
    Ichiyama, Takashi
    Komatsu, Masamichi
    Wada, Yosuke
    Hanaoka, Masayuki
    Ikegami, Shota
    Horiuchi, Hiroshi
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [2] Clinical characteristics and outcomes of patients with severe covid-19 with diabetes
    Yan, Yongli
    Yang, Yan
    Wang, Fen
    Ren, Huihui
    Zhang, Shujun
    Shi, Xiaoli
    Yu, Xuefeng
    Dong, Kun
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [3] Descriptive characteristics of continuous oximetry measurement in moderate to severe covid-19 patients
    Sobel, Jonathan A.
    Levy, Jeremy
    Almog, Ronit
    Reiner-Benaim, Anat
    Miller, Asaf
    Eytan, Danny
    Behar, Joachim A.
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01):
  • [4] Descriptive characteristics of continuous oximetry measurement in moderate to severe covid-19 patients
    Jonathan A. Sobel
    Jeremy Levy
    Ronit Almog
    Anat Reiner-Benaim
    Asaf Miller
    Danny Eytan
    Joachim A. Behar
    [J]. Scientific Reports, 13 (1)
  • [5] The clinical characteristics and risk factors for severe COVID-19 in patients with COVID-19 and tuberculosis coinfection
    Wang, Yang
    Chen, Yanping
    Gu, Lina
    Lou, Lixin
    Zhang, Jian
    Zhang, Kaiyu
    [J]. FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [6] Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Darazam, Ilad Alavi
    Shokouhi, Shervin
    Mardani, Masoud
    Pourhoseingholi, Mohamad Amin
    Rabiei, Mohammad Mahdi
    Hatami, Firouze
    Shabani, Minoosh
    Moradi, Omid
    Gharehbagh, Farid Javandoust
    Irvani, Seyed Sina Naghibi
    Amirdosara, Mahdi
    Hajiesmaeili, Mohammadreza
    Rezaei, Omidvar
    Khoshkar, Ali
    Lotfollahi, Legha
    Gachkar, Latif
    Dehbsneh, Hadiseh Shabanpour
    Khalili, Negar
    Soleymaninia, Azam
    Kusha, Akram Hoseyni
    Shoushtari, Maryam Taleb
    Torabinavid, Parham
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [7] Clinical characteristics of moderate and severe cases with COVID-19 in Wuhan, China: a retrospective study
    Sheng, Lingshuang
    Wang, Xiong
    Tang, Ning
    Meng, Fankai
    Huang, Liang
    Li, Dengju
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 21 (01) : 35 - 39
  • [8] Clinical characteristics of moderate and severe cases with COVID-19 in Wuhan, China: a retrospective study
    Lingshuang Sheng
    Xiong Wang
    Ning Tang
    Fankai Meng
    Liang Huang
    Dengju Li
    [J]. Clinical and Experimental Medicine, 2021, 21 : 35 - 39
  • [9] Residual symptoms in moderate to severe COVID-19 patients
    Elfidha, Sabrine
    Louhaichi, Sabrine
    Khalfallah, Ikbel
    Marzouki, Safa
    Kaabi, Line
    Jebeli, Rihab
    Kharrat, Mohamed Ali
    Ammar, Jamel
    Hamdi, Besma
    Hamzaoui, Agnes
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] The effect of Fingolimod on patients with moderate to severe COVID-19
    Teymouri, Soheil
    Kaleybar, Siamak Pourbayram
    Hejazian, Seyyed Sina
    Hejazian, Seyyedeh Mina
    Ansarin, Khalil
    Ardalan, Mohammadreza
    Vahed, Sepideh Zununi
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):